201 related articles for article (PubMed ID: 31289113)
1. In Vitro and In Silico Analyses of the Inhibition of Human Aldehyde Oxidase by Bazedoxifene, Lasofoxifene, and Structural Analogues.
Chen S; Austin-Muttitt K; Zhang LH; Mullins JGL; Lau AJ
J Pharmacol Exp Ther; 2019 Oct; 371(1):75-86. PubMed ID: 31289113
[TBL] [Abstract][Full Text] [Related]
2. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.
Peano BJ; Crabtree JS; Komm BS; Winneker RC; Harris HA
Endocrinology; 2009 Apr; 150(4):1897-903. PubMed ID: 19022889
[TBL] [Abstract][Full Text] [Related]
3. CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene.
Kumar P; Song ZH
Biochem Biophys Res Commun; 2014 Jan; 443(1):144-9. PubMed ID: 24275139
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
Tan WK; Tan ARY; Sivanandam P; Goh EJH; Yap ZP; Saburulla NF; Austin-Muttitt K; Mullins JGL; Lau AJ
J Pharmacol Exp Ther; 2020 Aug; 374(2):295-307. PubMed ID: 32393528
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Human Sulfotransferase 2A1-Catalyzed Sulfonation of Lithocholic Acid, Glycolithocholic Acid, and Taurolithocholic Acid by Selective Estrogen Receptor Modulators and Various Analogs and Metabolites.
Bansal S; Lau AJ
J Pharmacol Exp Ther; 2019 Jun; 369(3):389-405. PubMed ID: 30918069
[TBL] [Abstract][Full Text] [Related]
6. [Next generation selective estrogen receptor modulators].
Chaki O
Clin Calcium; 2006 Jan; 16(1):145-52. PubMed ID: 16397365
[TBL] [Abstract][Full Text] [Related]
7. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
Gennari L
Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.
Chang KC; Wang Y; Bodine PV; Nagpal S; Komm BS
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):117-24. PubMed ID: 19914376
[TBL] [Abstract][Full Text] [Related]
9. Lasofoxifene: CP 336156, CP-336156.
Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
[TBL] [Abstract][Full Text] [Related]
10. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
11. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis.
Andersson A; Bernardi AI; Stubelius A; Nurkkala-Karlsson M; Ohlsson C; Carlsten H; Islander U
Rheumatology (Oxford); 2016 Mar; 55(3):553-63. PubMed ID: 26424839
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators: the future in menopausal treatment.
Palacios S
Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612
[TBL] [Abstract][Full Text] [Related]
13. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
14. Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation.
Sudhakar R; Adhikari N; Pamnani S; Panda A; Bhattacharjee M; Rizvi Z; Shehzad S; Gupta D; Sijwali PS
Microbiol Spectr; 2022 Jun; 10(3):e0278121. PubMed ID: 35616371
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of human liver aldehyde oxidase by raloxifene.
Obach RS
Drug Metab Dispos; 2004 Jan; 32(1):89-97. PubMed ID: 14709625
[TBL] [Abstract][Full Text] [Related]
16. New selective estrogen receptor modulators (SERMs) in development.
Silverman SL
Curr Osteoporos Rep; 2010 Sep; 8(3):151-3. PubMed ID: 20603714
[TBL] [Abstract][Full Text] [Related]
17. SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway.
Matsushima-Nishiwaki R; Yamada N; Hattori Y; Hosokawa Y; Tachi J; Hori T; Kozawa O
PLoS One; 2022; 17(1):e0262485. PubMed ID: 35007301
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.
Gennari L; Merlotti D; Nuti R
Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039
[TBL] [Abstract][Full Text] [Related]
19. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado Martín PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
